Sarepta Therapeutics Inc
SRPTHealthcare|Biotechnology|USA
$22.07
-0.73 (-3.20%)
Tangible Book
$10.59
About
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Stock Price
-61.1%(1Y)
Pipeline Summary
55 total trials28
Phase 1
20
Phase 2
9
Phase 3
1
Phase 4
Active: 6Completed: 26Terminated: 15ENROLLING_BY_INVITATION: 4Recruiting: 2Withdrawn: 2
Active Trials (8)
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Phase 3Active
Enrollment: 160 participants
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Phase 2Active
Enrollment: 13 participants
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Phase 3Active
Enrollment: 148 participants
Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies
NCT06581887DMD
Recruiting
Enrollment: 100 participants
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Limb-girdle Muscular Dystrophy
Phase 3Active
Enrollment: 17 participants
BioScore
7/10
Buy
Ownership
Recent Insider Trades
Mayo StephenSELL
2026-03-127,239 shares @ $17.02
Estepan Ian MichaelSELL
2025-12-1613,187 shares @ $22.31
Nicaise ClaudeSELL
2025-03-122,491 shares @ $99.64
Wigzell Hans Lennart RudolfSELL
2024-12-1210,500 shares @ $124.84
Boor Kathryn JeanSELL
2024-12-051,636 shares @ $125.55
Recent News
2026-03-31 21:00:07
2026-03-26 16:01:03
2026-03-26 13:29:54
2026-03-26 12:32:21
2026-03-25 17:00:28
Data last updated: Apr 7, 2026, 02:28 PM